New insider activity at Compass Therapeutics ( (CMPX) ) has taken place on April 12, 2025.
In a significant move, Director Carl Gordon and Director Orbimed Advisors LLC have each sold 3,571,428 shares of Compass Therapeutics stock. These transactions are valued at $5,678,570 each, marking a notable shift in the company’s stock holdings.
Recent Updates on CMPX stock
In the last 24 hours, Compass Therapeutics has seen significant developments following the release of positive top-line results from its Phase 2/3 COMPANION-002 trial. The trial evaluated the efficacy of tovecimig in combination with paclitaxel for advanced biliary tract cancer, showing a statistically significant improvement in overall response rate compared to paclitaxel alone. This promising data has led to several analysts raising their price targets for Compass Therapeutics. H.C. Wainwright increased their target due to the potential of tovecimig becoming a standard of care in second-line BTC. Leerink upgraded the stock to Outperform, acknowledging the trial’s success despite initial concerns about efficacy risks. Stifel also raised their target, emphasizing the importance of achieving statistical significance in overall response rate, which could lead to meaningful clinical outcomes. These developments highlight the potential of tovecimig as a much-needed treatment option for BTC patients with limited alternatives.
Spark’s Take on CMPX Stock
According to Spark, TipRanks’ AI Analyst, CMPX is a Neutral.
Compass Therapeutics’ stock is moderately attractive, driven by strong market momentum and strategic leadership changes. However, significant operational losses, negative cash flows, and lack of current profitability weigh down the financial performance score. While technical indicators are positive, valuation remains a concern due to the negative P/E ratio.
To see Spark’s full report on CMPX stock, click here.
More about Compass Therapeutics
YTD Price Performance: 17.86%
Average Trading Volume: 1,786,333
Technical Sentiment Signal: Strong Buy
Current Market Cap: $242M